GT Biopharma (GTBP) Asset Writedowns and Impairment (2018 - 2020)
GT Biopharma (GTBP) posted quarterly Asset Writedowns and Impairment of $15000.0 for Q3 2020, down 99.99% quarter-over-quarter from $228.5 million in Q3 2018.
GT Biopharma (GTBP) Asset Writedowns and Impairment (2018 - 2020) Analysis & Trends
GT Biopharma (GTBP) has reported Asset Writedowns and Impairment for 2 consecutive years, with $15000.0 the latest figure, recorded in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 15,000.00 |
| Sep 30, 2020 | 15,000.00 |
| Sep 30, 2018 | 228.51 Mn |
| Sep 30, 2018 | 228.51 Mn |